Analysts expect Glaukos Corp (NYSE:GKOS) to announce earnings of ($0.02) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Glaukos’ earnings. The lowest EPS estimate is ($0.11) and the highest is $0.11. Glaukos posted earnings of $0.03 per share in the same quarter last year, which would suggest a negative year over year growth rate of 166.7%. The firm is expected to report its next earnings report on Wednesday, February 27th.
On average, analysts expect that Glaukos will report full-year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.49) to ($0.18). For the next financial year, analysts expect that the firm will post earnings of $0.19 per share, with EPS estimates ranging from ($0.03) to $0.41. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Glaukos.
Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, November 7th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Glaukos had a negative return on equity of 4.11% and a negative net margin of 3.49%. The firm had revenue of $43.91 million for the quarter, compared to analysts’ expectations of $41.65 million. During the same quarter last year, the firm posted $0.04 earnings per share. Glaukos’s quarterly revenue was up 8.7% on a year-over-year basis.
A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Glaukos from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research report on Tuesday, August 7th. Berenberg Bank assumed coverage on Glaukos in a research report on Thursday, August 30th. They issued a “hold” rating and a $57.00 price target for the company. Stifel Nicolaus upped their price target on Glaukos from $32.00 to $35.00 and gave the company a “hold” rating in a research report on Friday, August 3rd. BMO Capital Markets upped their price target on Glaukos from $59.00 to $62.00 and gave the company a “market perform” rating in a research report on Thursday, August 30th. Finally, Wells Fargo & Co upped their price target on Glaukos from $50.00 to $74.00 and gave the company an “outperform” rating in a research report on Thursday, August 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $58.20.
NYSE:GKOS opened at $61.28 on Friday. Glaukos has a 12 month low of $23.08 and a 12 month high of $70.91.
In other news, Director Gilbert H. Kliman sold 502,760 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $60.39, for a total value of $30,361,676.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of GKOS. NumerixS Investment Technologies Inc purchased a new position in Glaukos in the second quarter worth approximately $127,000. Great West Life Assurance Co. Can grew its position in Glaukos by 112.0% in the second quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 2,240 shares during the period. Valeo Financial Advisors LLC purchased a new position in Glaukos in the second quarter worth approximately $183,000. Prudential Financial Inc. purchased a new position in Glaukos in the third quarter worth approximately $203,000. Finally, Amalgamated Bank purchased a new position in Glaukos in the second quarter worth approximately $205,000.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Recommended Story: Stock Selection – What is cash flow?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.